Vaccine shield tested: do immunocompromised patients get enough protection?
NCT ID NCT04952766
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study looked at how well the Pfizer COVID-19 vaccine works in adults with weakened immune systems (like kidney transplant patients, people with cancer, or those on dialysis) compared to healthy adults. Researchers measured antibody levels and their ability to neutralize the virus. The goal was to understand if these vulnerable groups get the same protection as healthy people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Orléans
Orléans, 45067, France
Conditions
Explore the condition pages connected to this study.